Craig Venter's Latest Startup Gets $70 Million to Sequence Loads of Genomes

The human genome pioneer has unveiled a venture to provide whole genome sequencing and cell-therapy-based diagnostic services for patients.

Mar 4, 2014 at 5:29PM

J. Craig Venter, the human genome pioneer, today unveiled a new San Diego-based venture with an ambitious goal of providing whole genome sequencing and cell-therapy-based diagnostic services for patients.

Venter said he co-founded the company, Human Longevity, or HLI, with Robert Hariri, who oversaw Celgene Cellular Therapeutics and Peter Diamandis of the X Prize Foundation. The company already has raised $70 million in Series A venture financing that includes a Malaysian investment fund that also is the lead investor of another Venter venture, Synthetic Genomics, San Diego-based Illumina, and other individual investors.

Venter plans to serve as the chairman and CEO of both HLI and San Diego-based Synthetic Genomics, which he co-founded in 2005 to engineer genes within organisms so they can produce fuel, chemicals, medicines, and nutritional products.

The HLI effort, which Venter and others repeatedly described as "unprecedented" in a conference call this morning, will initially focus on basic research and development, sequencing every cancer patient who comes into the UC San Diego Moores Cancer Center, as well as other patients with diabetes, obesity, heart and liver diseases, and dementia.

In a statement this morning, HLI says it has established collaborative research and development partnerships with UC San Diego, Metabolon, and the J. Craig Venter Institute. North Carolina-based Metabolon is expected to provide information about patients' metabolytes, key chemicals in their blood.

HLI also has formed a Biome Healthcare division, led by Karen Nelson, to generate gene sequencing data of the microbiome for many patients. The microbiome consists of all the microbes that live in the human gut (and elsewhere in and on the human body). New research by Nelson and others suggest that such bacteria play a key role in human health and disease.

The early goal at HLI is to sequence 40,000 human genomes a year, and amass the world's largest database of human genome sequences. HLI plans to combine its human genome data with microbiome data and phenotype databases to develop new treatments, including stem cell therapies, for aging-related diseases. Eventually, HLI intends to sequence 100,000 human genomes a year.

"We will be using that [data] to make numerous new discoveries in preventative medicine," Venter said. "We think this will have a huge impact on changing the cost of medicine and broad human health."

HLI plans to make money by providing access to its database to pharmaceutical, biotechnology and academic organizations, gene sequencing, and by developing new medical diagnostics and therapeutics. As HLI's genome-sequencing capacity increases, the company plans to sequence people of all ages -- from infants to super centenarians -- including those who are healthy as well as those with disease.

Genomic data would be shared among researchers participating in the effort, although Venter said details about protecting patient privacy are still being worked out.

DFJ partner Steve Jurvetson, who said he's an investor in HLI, asked Venter during the call to compare the effort to BGI China, one of the world's premier gene sequencing centers. BGI says on its U.S. website that it has relationships with 17 out of the top 20 global pharmaceutical companies as part of its suite of commercial science, health, agricultural, and informatics services.

Venter answered that HLI will be working with more advanced gene sequencing equipment (Illumina's HiSeq X Ten Sequencing Systems) and will have higher throughput capabilities. But he added that there is plenty of room for gene sequencing services. In fact, Venter envisions a future where genome sequencing is done routinely for every patient admitted to a hospital.

"We cannot have enough players in the human genome sequencing field," Venter said. "We're just trying to elevate it to a new level."

With $70 million in initial funding, "We think that will carry us through the first 18 months as we build these operations," Venter said. HLI already is using laboratories in San Diego for high-throughput microbiome and human genome sequencing, and has plans to build a new facility near the UC San Diego campus. HLI plans to hire about 100 scientists and others over the next year, Venter said.

"This is a revolution in biomedical research," said David A. Brenner, vice chancellor for health sciences and dean of the UC San Diego School of Medicine. "This is the first time ever as physician-scientists that we have had the opportunity to handle very large datasets and to be able to compare the genetics of a patient with the microbiome, as Dr. Nelson said, and with the metabolytes in the blood to try to gain new insights into our understanding of disease pathogenesis, into diagnoses, and hopefully, into new therapies and cures."

Biotech isn't the only revolutionary industry that investors are talking about
For the first time since the early days of this country, we're in a position to dominate the global manufacturing landscape thanks to a single, revolutionary technology: 3D printing. Although this sounds like something out of a science fiction novel, the success of 3D printing is already a foregone conclusion to many manufacturers around the world. The trick now is to identify the companies -- and thereby the stocks -- that will prevail in the battle for market share. To see the three companies that are currently positioned to do so, simply download our invaluable free report on the topic by clicking here now.

This article originally appeared on Xconomy, along with:

Bruce V. Bigelow has no position in any stocks mentioned. The Motley Fool recommends Celgene and Illumina. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information